Table 3.
Univariate Analysis of Prognostic Factors for Disease-Free Survival in Propensity Score-Matched Patients Screened for EML4-ALK Rearrangement
| Variables | All Patients (N=280) | Female Patients (N=113) | Male Patients (N=167) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | P-value | HR | 95% CI | P-value | HR | 95% CI | P-value | |
| Age | 1.02 | 0.99–1.04 | 0.241 | 1.01 | 0.97–1.04 | 0.655 | 1.02 | 0.99–1.06 | 0.216 |
| Gender | |||||||||
| Female | Ref | / | / | ||||||
| Male | 1.30 | 0.81–2.07 | 0.281 | / | / | ||||
| Smoking history | |||||||||
| Never | Ref | Ref | Ref | ||||||
| Ever | 1.38 | 0.77–2.48 | 0.279 | 3.20 | 0.44–23.32 | 0.251 | 1.65 | 0.82–3.34 | 0.164 |
| Tumor size | 1.05 | 1.03–1.06 | <0.001 | 1.04 | 1.01–1.07 | 0.003 | 1.05 | 1.03–1.07 | <0.001 |
| Pathological T-stage | |||||||||
| T1 | Ref | Ref | Ref | ||||||
| T2 | 2.21 | 1.33–3.65 | 0.002 | 2.02 | 1.04–3.91 | 0.038 | 2.42 | 1.10–5.32 | 0.028 |
| T3 | 6.80 | 2.59–17.85 | <0.001 | 3.60 | 0.82–15.75 | 0.089 | 17.23 | 4.58–64.83 | <0.001 |
| Trend | 2.40 | 1.58–3.65 | <0.001 | 1.96 | 1.14–3.39 | 0.016 | 3.27 | 1.64–6.54 | 0.001 |
| Pathological N-stage | |||||||||
| N0 | Ref | Ref | Ref | ||||||
| N1 | 2.73 | 1.06–7.01 | 0.037 | 3.31 | 0.98–11.20 | 0.054 | 2.08 | 0.47–9.22 | 0.336 |
| N2 | 7.62 | 4.66–12.45 | <0.001 | 7.29 | 3.72–14.28 | <0.001 | 7.90 | 3.80–16.45 | <0.001 |
| Trend | 2.76 | 2.16–3.53 | <0.001 | 2.70 | 1.94–3.78 | <0.001 | 2.82 | 1.95–4.08 | <0.001 |
| Preoperative CEA | |||||||||
| <5 | Ref | Ref | Ref | ||||||
| ≥5 | 3.00 | 1.83–4.91 | <0.001 | 2.94 | 1.39–6.21 | 0.005 | 3.10 | 1.54–6.25 | 0.002 |
| Postoperative chemotherapy | |||||||||
| No | Ref | Ref | Ref | ||||||
| Yes | 3.61 | 2.07–6.31 | <0.001 | 3.55 | 1.72–7.31 | 0.001 | 3.59 | 1.48–8.74 | 0.005 |
| EML4-ALK rearrangement | |||||||||
| Negative | Ref | Ref | Ref | ||||||
| Positive | 1.43 | 0.86–2.37 | 0.164 | 2.10 | 1.10–4.04 | 0.026 | 0.81 | 0.35–1.89 | 0.632 |
Abbreviations: EML4, echinoderm microtubule-associated protein-like 4; ALK, anaplastic lymphoma kinase; CEA, carcino-embryonic antigen; HR, hazard ratio; CI, confidence interval; Ref, reference.